{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.18","value":"-1.1"},{"groupId":"OG001","spread":"0.78","value":"-0.8"},{"groupId":"OG002","spread":"1.39","value":"-1.1"},{"groupId":"OG003","spread":"1.18","value":"-1.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"123"}],"units":"Participants"}],"description":"Core phase - Changes in standardized IGF-1 from study baseline to week 36.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were treated with lanreotide 120mg and assigned to Group 2 (before starting on Pasireotide in the Core phase).","id":"OG000","title":"Lanreotide 120 mg"},{"description":"Participants were treated with octreotide 30 mg and assigned to Group 2 (before starting on Pasireotide in the Core phase). .","id":"OG001","title":"Octreotide 30 mg"},{"description":"Participants were treated with octreotide 40 mg and assigned to either Group 1 (if 40mg octreotide was approved in the country) or Group 2 if 40mg octreotide was not approved in the country (before starting on Pasireotide in the Core phase).","id":"OG002","title":"Octreotide 40 mg"},{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.","id":"OG003","title":"Pasireotide LAR Overall"}],"paramType":"MEAN","populationDescription":"FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study.","reportingStatus":"POSTED","timeFrame":"Baseline, week 36","title":"Core Phase: Change in Standardized IGF-1 Values From Baseline to Week 36","type":"SECONDARY","unitOfMeasure":"percentage change"}